How to Mitigate Risks in MS
9th December 2021, Pre-MENACTRIMS symposium, as a warm-up for the Sixth MENACTRIMS Congress, ParadigMS Foundation organised this enriching Pre-MENACTRIMS Symposium. Here you can review the full keynote on how to mitigate risks in MS.
ABSTRACT
No two MS patients are the same, and yet only a limited number of disease-modifying therapies are available for MS neurologists to treat their patients. This session guides you in how to manage and mitigate risks associated with treating MS patients. You will take away a set of key messages stemming both from Professor Pugliatti’s own experience and literature reports, underlying risk mitigation in MS treatment.
MAURA PUGLIATTI
Professor Neurology at University of Ferrara
Maura PUGLIATTI, MD, PhD is Full Professor of Neurology at the University of Ferrara, Director of the University Hospital Unit of Clinical Neurology, S. Anna Hospital, Ferrara, Italy. She is also Director of the Residency School of Neurology at the same University. In 2007 she took a PhD and in 2007-10 was Research Fellow at the Dept. of Public Health and Primary Health Care, University of Bergen, Norway, actively coordinating a large multi-center case-control study on multiple sclerosis and environmental risk factors. Since 2011 she is Adjunct Professor at the Dept. of Clinical Medicine, McGill University, Montreal, Canada within collaborative research in MS epidemiology. She has been Visiting Professor at the University of Bergen (Erasmus Teaching Staff Mobility program to medical students, 2010-12), University of Belgrade, Serbia (to PhD student, 2015), and has been a faculty member of the PhD School in at the University of Medicine and Pharmacy, Cluj Napoca, Romania, since 2016. In 2008-14 she was Chair of the EFNS Scientist Panel of Neuroepidemiology and Public Health, and has co-chaired the same Panel for the European Academy of Neurology in 2015-18. She is a member of ParadigMS Foundation founders.
Her main research areas are multiple sclerosis, epidemiology of amyotrophic lateral sclerosis, through collaborative research at national and international level. She is author of 137 papers in peer-reviewed scientific journals, has a total impact factor > 500 and H-index=37.